| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | 15.27 | 20.96 | 22.83 | 24.54 | 33.07 | 2.43 |
| Quick Ratio | 15.27 | 20.96 | 22.83 | 24.54 | 33.07 | 2.43 |
| Debt / Equity | — | — | — | — | — | — |
| ROE | -34.08% | -24.37% | -18.02% | -17.68% | -16.26% | 46.47% |
| ROA | -30.11% | -22.84% | -17.23% | -16.97% | -15.77% | -136.73% |
| Asset Turnover | — | — | — | — | — | — |
| Book Value / Share | 17.17 | 16.11 | 12.03 | 9.32 | 13.08 | -10.92 |
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. The company applies structure-based drug design and chemistry expertise to create small-molecule treatments aimed at clinically proven kinase targets, with an emphasis on improving selectivity and addressing resistance mechanisms. Its current programs center on non-small cell lung cancer, including therapies for ROS1-positive and ALK-positive disease, as well as a HER2-altered program in early clinical development. Nuvalent’s work is positioned within the oncology sector, where it contributes to the development of targeted medicines intended to support more durable responses and better tolerability across patient populations.